In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics company. Three cancer test launches, multiple study readouts and one $23 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Abbott Laboratories is making ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

ABBOTT PARK, Ill./MADISON, Wis. — Abbott Laboratories, headquartered in north suburban Abbott Park, will acquire Madison, Wisconsin-based Exact Sciences, the companies announced in a news release ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Abbott said Thursday it would buy Exact Sciences, the maker of tests ...

Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics ...

Investing.com -- Exact Sciences (NASDAQ:EXAS) stock soared 17% Thursday, building on Wednesday’s 24% surge after Abbott (NYSE:ABT) announced plans to acquire the cancer diagnostics company in a deal ...

Abbott Laboratories could be looking to acquire Exact Sciences, according to a report from Bloomberg, citing people close to the deal. News of the rumored deal caused Madison, WI-based Exact Sciences ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal ...

Exact Sciences (EXAS) will likely need to see over $100 a share in a takeover, according to a William Blair analyst, after an earlier report that Abbott Labs (ABT) is in talks to buy the cancer test ...

The cancer diagnostics specialist might, just might, be on the verge of selling itself. The apparent would-be buyer is a top name in the U.S. pharmaceutical industry. A strategic investor is ...